Status:
COMPLETED
Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed. This may be effective against non-small...
Detailed Description
OBJECTIVES: Primary * To test the hypothesis that the immune response in non-small cell lung cancer patients treated with photodynamic therapy (PDT) is T cell mediated. Secondary * To test the hyp...
Eligibility Criteria
Inclusion
- Patients that have a diagnosis of non-small cell lung cancer, of any stage, with obstructive or hemorrhagic endobronchial disease receiving PDT treatment.
Exclusion
- Patients that have undergone PDT, chemotherapy or radiation therapy within the past 3 months will not be considered for enrollment.
- Patients taking antioxidant therapy will be excluded from enrollment due to potential interaction with the potential oxidative mechanism of action of Photofrin®. These antioxidants would include beta-carotene, lutein, Lycopene, Selenium, Vitamin A, Vitamin C, Vitamin E.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00754910
Start Date
December 1 2008
End Date
March 1 2016
Last Update
July 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University Medical Center
Columbus, Ohio, United States, 43210-1240